Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.35
DYAX's Cash to Debt is ranked higher than
58% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. DYAX: 1.35 )
DYAX' s 10-Year Cash to Debt Range
Min: 0.37   Max: 32.79
Current: 1.35

0.37
32.79
Equity to Asset 0.20
DYAX's Equity to Asset is ranked higher than
51% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DYAX: 0.20 )
DYAX' s 10-Year Equity to Asset Range
Min: -0.93   Max: 0.76
Current: 0.2

-0.93
0.76
F-Score: 4
Z-Score: 0.17
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -31.89
DYAX's Operating margin (%) is ranked higher than
74% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. DYAX: -31.89 )
DYAX' s 10-Year Operating margin (%) Range
Min: -389.57   Max: -27.65
Current: -31.89

-389.57
-27.65
Net-margin (%) -51.51
DYAX's Net-margin (%) is ranked higher than
71% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. DYAX: -51.51 )
DYAX' s 10-Year Net-margin (%) Range
Min: -393.89   Max: -44
Current: -51.51

-393.89
-44
ROE (%) -105.53
DYAX's ROE (%) is ranked higher than
54% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. DYAX: -105.53 )
DYAX' s 10-Year ROE (%) Range
Min: -930.61   Max: -21.74
Current: -105.53

-930.61
-21.74
ROA (%) -20.70
DYAX's ROA (%) is ranked higher than
70% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. DYAX: -20.70 )
DYAX' s 10-Year ROA (%) Range
Min: -96.32   Max: -10.42
Current: -20.7

-96.32
-10.42
ROC (Joel Greenblatt) (%) -346.75
DYAX's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. DYAX: -346.75 )
DYAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1541.42   Max: -138.92
Current: -346.75

-1541.42
-138.92
Revenue Growth (%) -3.10
DYAX's Revenue Growth (%) is ranked higher than
72% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. DYAX: -3.10 )
DYAX' s 10-Year Revenue Growth (%) Range
Min: -37.4   Max: 21.1
Current: -3.1

-37.4
21.1
EBITDA Growth (%) 7.70
DYAX's EBITDA Growth (%) is ranked higher than
86% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. DYAX: 7.70 )
DYAX' s 10-Year EBITDA Growth (%) Range
Min: -49.1   Max: 10.4
Current: 7.7

-49.1
10.4
» DYAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

DYAX Guru Trades in Q1 2013

Steven Cohen 100,000 sh (New)
Jim Simons 127,025 sh (+35.42%)
Chuck Royce 1,956,300 sh (unchged)
PRIMECAP Management 8,732,900 sh (unchged)
» More
Q2 2013

DYAX Guru Trades in Q2 2013

Steven Cohen 140,000 sh (+40%)
PRIMECAP Management 10,906,810 sh (+24.89%)
Jim Simons Sold Out
Chuck Royce 1,434,000 sh (-26.7%)
» More
Q3 2013

DYAX Guru Trades in Q3 2013

Jim Simons 94,400 sh (New)
PRIMECAP Management 10,906,990 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 1,059,000 sh (-26.15%)
» More
Q4 2013

DYAX Guru Trades in Q4 2013

Paul Tudor Jones 54,343 sh (New)
Jim Simons 528,000 sh (+459.32%)
PRIMECAP Management 11,806,990 sh (+8.25%)
Chuck Royce 809,000 sh (-23.61%)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2013-06-30 Add 24.89%0.01%$2.29 - $4.42 $ 6.8109%10906810
PRIMECAP Management 2012-09-30 New Buy0.04%$2.13 - $2.75 $ 6.8174%8732900
PRIMECAP Management 2012-06-30 Sold Out 0.02%$1.48 - $2.19 $ 6.8291%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 30.90
DYAX's P/B is ranked lower than
75% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. DYAX: 30.90 )
DYAX' s 10-Year P/B Range
Min: 2.05   Max: 74.67
Current: 30.9

2.05
74.67
P/S 13.68
DYAX's P/S is ranked lower than
54% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. DYAX: 13.68 )
DYAX' s 10-Year P/S Range
Min: 2.41   Max: 22.08
Current: 13.68

2.41
22.08
EV-to-EBIT 17.90
DYAX's EV-to-EBIT is ranked higher than
61% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. DYAX: 17.90 )
DYAX' s 10-Year EV-to-EBIT Range
Min: 13.7   Max: 87.5
Current: 17.9

13.7
87.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 226.70
DYAX's Price/Net Cash is ranked lower than
95% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. DYAX: 226.70 )
DYAX' s 10-Year Price/Net Cash Range
Min: 7.57   Max: 251.17
Current: 226.7

7.57
251.17
Price/Net Current Asset Value 85.00
DYAX's Price/Net Current Asset Value is ranked lower than
90% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. DYAX: 85.00 )
DYAX' s 10-Year Price/Net Current Asset Value Range
Min: 6.61   Max: 94.19
Current: 85

6.61
94.19
Price/Tangible Book 30.90
DYAX's Price/Tangible Book is ranked lower than
87% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. DYAX: 30.90 )
DYAX' s 10-Year Price/Tangible Book Range
Min: 1.29   Max: 72
Current: 30.9

1.29
72
Price/Median PS Value 1.80
DYAX's Price/Median PS Value is ranked lower than
58% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. DYAX: 1.80 )
DYAX' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 2.03
Current: 1.8

0.16
2.03
Forward Rate of Return (Yacktman) -28.96
DYAX's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. DYAX: -28.96 )
DYAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -88.3   Max: -15.4
Current: -28.96

-88.3
-15.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DY8.Germany
Dyax Corp. is incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. The company a biopharmaceutical company with two business elements: Plasma Kallikrein-Mediated Angioedema Portfolio - The principal focus of its efforts is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE) and angioedema of unknown origin, or idiopathic angioedema. It developed KALBITOR (ecallantide) on its own and since February 2010, it has been selling it in the United States for the treatment of acute attacks of HAE; and Phage Display Licensing and Funded Research Program- leverage its proprietary phage display technology through Licensing and Funded Research Program, referred to as the LFRP. This program has provided the company a portfolio of product candidates being developed by licensees, which currently includes 13 product candidates in clinical development, including four products in Phase 3 trials. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. Using phage display technology, it developed ecallantide, a compound shown in vitro to be a high affinity, high specificity inhibitor of human plasma kallikrein. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR, are subject to extensive regulation by governmental authorities in the United States and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide